We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00382174
First Posted: September 28, 2006
Last Update Posted: February 1, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
RegeneRx Biopharmaceuticals, Inc.
  Purpose
The purpose of this study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Pressure Ulcers

Condition Intervention Phase
Pressure Ulcers Drug: Placebo Drug: Thymosin Beta 4 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Pressure Ulcers

Resource links provided by NLM:


Further study details as provided by RegeneRx Biopharmaceuticals, Inc.:

Primary Outcome Measures:
  • Safety and Tolerability of Thymosin Beta 4 (Tβ4)Applied for up to 84 Days [ Time Frame: Up to 84 days ]

Secondary Outcome Measures:
  • Wound Healing Effectiveness of Tβ4 Applied for up to 84 Days [ Time Frame: Up to 84 days ]

Enrollment: 72
Study Start Date: May 2006
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
Drug: Placebo
Topical administration of 0.00% thymosin beta 4 qd up to 84 days
Active Comparator: 2
3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
Drug: Thymosin Beta 4
Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days

Detailed Description:
The purpose of this double-blind, placebo-controlled, dose-escalation study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 (Tβ4), administered topically, in patients with Pressure Ulcers (PU). PU is caused by prolonged pressure or rubbing of the body in areas prone to moisture and friction. PU affects primarily elderly, bedridden patients. Tβ4 is a synthetically-produced copy of a naturally-occurring 43 amino acid peptide that has wound healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Informed Consent Form signed by the patient or patient's legal representative
  • Inpatients and outpatients
  • At least 1 PU with full-thickness skin loss and no joint capsule or bone exposure
  • Surface area between 5 and 70 cm2
  • Ulcer present and stable for at least 1 month before enrollment

Exclusion Criteria:

  • Use of any experimental drug, or participation in any clinical study, within the 60 days before enrollment
  • Use of immunotherapy, or cytotoxic chemotherapy within the 60 days before enrollment. Systemic steroids not allowed 30 days prior to enrollment. Topical therapy other than steroidal is allowed up to 7 days prior to enrollment
  • History of adverse events to any ingredients of study medication
  • Neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease likely to interfere with the patient's participation in or completion of the study
  • Arterial or venous disorder resulting in ulcerated wounds
  • Diabetes mellitus except if disease is determined to be under control with a glycosylated hemoglobin ≤8.5% of total hemoglobin
  • Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed at Screening for female patients of childbearing potential.)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382174


Locations
United States, Alabama
Institute for Advanced Wound Care
Montgomery, Alabama, United States, 36111
United States, California
Impact Clinical Trials
Beverly Hills, California, United States, 90211
Long Beach VAMC
Long Beach, California, United States, 90822
United States, Florida
Bay Pines VA Medical Center
Bay Pines, Florida, United States, 33744
A+ Research, Inc.
Miami, Florida, United States, 33115
Mount Dora Research Center, Inc.
Mount Dora, Florida, United States, 32757
United States, Illinois
Hines VAMC
Hines, Illinois, United States, 60141
United States, Massachusetts
Wound Healing Laboratory Plastic Surgery UMass Medical Center
Worcester, Massachusetts, United States, 01655
United States, New York
New York Presbyterian Hospital
New York, New York, United States, 10032
United States, North Carolina
University of North Carolina Hospital
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
New Bridge Medical Center
Warren, Pennsylvania, United States, 16365
United States, Virginia
Mcguire VA Medical Center
Richmond, Virginia, United States, 23249
Sponsors and Collaborators
RegeneRx Biopharmaceuticals, Inc.
Investigators
Principal Investigator: Terry Treadwell, MD Institute for Advanced Wound Care
  More Information

Responsible Party: David Crockford, VP, Clinical and Regulatory Affairs, RegeneRx Biopharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00382174     History of Changes
Other Study ID Numbers: SSPU
First Submitted: September 26, 2006
First Posted: September 28, 2006
Results First Submitted: December 29, 2009
Results First Posted: February 1, 2010
Last Update Posted: February 1, 2010
Last Verified: January 2010

Keywords provided by RegeneRx Biopharmaceuticals, Inc.:
pressure ulcers
cutaneous wound- healing
chronic wound-healing
Thymosin Beta 4
laminin-5

Additional relevant MeSH terms:
Ulcer
Pressure Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases